Glasgow-based DeepMatter Group plc, the AIM-listed company focusing on digitizing chemistry, announced that one of its wholly owned subsidiaries has entered into a multi-year, limited-use data licensing agreement with the life science business of Merck to provide “proprietary chemical structure and reaction data content to Merck’s selected application.”

The terms of the data license agreement have not been disclosed.

DeepMatter CEO Mark Warne said: “We are delighted to have entered into this license with Merck, a company dedicated to making research and biotech simpler, faster and safer.”